Acute Lymphoblastic Leukemia (ALL): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Acute lymphoblastic leukemia (ALL) is a malignant clonal proliferation of immature B- or T-cell lymphoid precursors (lymphoblasts) that accumulate in the bone marrow, blood, and extramedullary sites, suppressing normal hematopoiesis. ALL is the most common cancer in children, accounting for approximately 75% of pediatric leukemias with a peak incidence at ages 2-5 years, and approximately 6,000 new US cases annually across all ages. In adults, ALL has a median diagnosis age of 35 years with a second incidence peak after age 60. Pediatric ALL has been transformed into one of oncology's greatest success stories: 5-year survival exceeds 90% in children with modern multi-agent therapy. Adult ALL remains significantly more challenging — 5-year overall survival is 35-55%, reflecting the higher incidence of adverse cytogenetics including the Philadelphia chromosome (BCR-ABL1 fusion, present in approximately 25% of adult ALL), T-cell ALL, and central nervous system disease. Key molecular subtypes include Ph-positive ALL (BCR-ABL1), Ph-like ALL (same gene expression profile as Ph+ but without the translocation), ETV6-RUNX1 ALL (favorable, common in children), and KMT2A-rearranged ALL (high-risk).

Most childhood ALL arises from a combination of inherited genetic susceptibility and acquired somatic mutations in lymphoid progenitor cells during fetal or early postnatal development. Established hereditary risk factors include Down syndrome (trisomy 21 — 20-fold increased ALL risk, particularly B-ALL), Klinefelter syndrome, Fanconi anemia, ataxia-telangiectasia (ATM mutation), Li-Fraumeni syndrome (TP53 germline), and Bloom syndrome. The BCR-ABL1 Philadelphia chromosome [t(9;22)(q34;q11.2)] is the defining genetic alteration in approximately 25% of adult ALL and confers high risk, requiring TKI addition to chemotherapy. Ph-like ALL harbors ABL-class fusions (CRLF2, JAK1/2 mutations) with a Ph+ gene expression signature but responds to TKI therapy. Environmental risk factors include in utero radiation exposure (atomic bomb survivors), postnatal high-dose ionizing radiation, and benzene exposure (particularly for adult ALL). Specific childhood infections (influenza, EBV) during a susceptible developmental window may trigger oncogenic chromosomal rearrangements in genetically predisposed children — the Kinlen hypothesis for childhood ALL clusters.

ALL typically presents with rapid onset of symptoms reflecting bone marrow failure and blast infiltration of organs, usually developing over days to weeks. Bone marrow suppression causes: fatigue, progressive pallor, and exertional dyspnea from anemia; unexplained fever and recurrent bacterial or fungal infections from neutropenia (absolute neutrophil count below 500 cells/μL); easy bruising, petechiae (pinpoint cutaneous hemorrhages), epistaxis, and mucosal bleeding from thrombocytopenia. Blast infiltration produces: bone and joint pain (a classic childhood ALL symptom, often misdiagnosed as growing pains or arthritis — present in 25-30% of children); diffuse lymphadenopathy (cervical, axillary, inguinal node enlargement); hepatosplenomegaly causing abdominal fullness; mediastinal lymphadenopathy (T-ALL can produce a mediastinal mass causing superior vena cava syndrome with facial swelling and respiratory distress — a medical emergency). CNS involvement at diagnosis: headache, cranial nerve palsies (diplopia, facial asymmetry), papilledema, or rarely altered consciousness. Constitutional symptoms: fever, night sweats, and weight loss.

Diagnosis requires demonstration of 20% or more lymphoblasts in bone marrow aspirate. Peripheral blood smear frequently shows circulating blasts with high white cell count (leukocytosis) or paradoxically low counts. Flow cytometry is essential for lineage determination: B-ALL immunophenotype (CD19+, CD10+, TdT+, CD34+, surface Ig−); T-ALL (CD3+, CD7+, CD2+, TdT+). Cytogenetic analysis (standard karyotype), FISH, and RT-PCR detect critical risk-stratifying translocations and mutations: BCR-ABL1 (Ph+, high-risk), ETV6-RUNX1 (favorable), KMT2A rearrangement (high-risk), iAMP21 (high-risk), hyperdiploidy (favorable, >50 chromosomes), hypodiploidy (high-risk, <44 chromosomes). Next-generation sequencing panels identify CRLF2, JAK2, FLT3, NOTCH1, FBXW7 mutations enabling Ph-like ALL classification. Lumbar puncture with CSF analysis evaluates CNS involvement (CNS1: no blasts; CNS2: blasts without pleocytosis; CNS3: ≥5 WBC with blasts — requires treatment intensification). Minimal residual disease (MRD) by quantitative PCR or flow cytometry after induction is the most powerful prognostic factor and guides therapy intensification decisions.

ALL treatment consists of three sequential phases: induction, consolidation, and maintenance. Induction chemotherapy (4-6 weeks): the goal is complete morphological remission (less than 5% blasts) and MRD negativity. Pediatric regimens — VAMP (vincristine, doxorubicin, methotrexate, prednisone) or augmented BFM-style protocols — achieve complete remission in over 95% of children. Adult regimens — hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate and cytarabine) — achieve complete remission in 80-90% of adults. Philadelphia chromosome-positive ALL: TKI (dasatinib 140 mg daily preferred for CNS penetration, or ponatinib in BCR-ABL1 kinase domain mutation-refractory cases) added to chemotherapy from induction — improves complete remission rates above 90% and is now standard of care. CNS prophylaxis: intrathecal methotrexate (with or without cytarabine and hydrocortisone) at regular intervals throughout therapy has replaced cranial radiation, preserving neurocognitive function. Consolidation: 6-8 months of intensified multiagent chemotherapy blocks including high-dose methotrexate, L-asparaginase, and 6-mercaptopurine. Maintenance: oral 6-mercaptopurine daily plus weekly methotrexate for 2-3 years is standard — a critical phase that ensures sustained remission. Allogeneic stem cell transplantation in first complete remission: recommended for Ph+ ALL achieving MRD negativity after TKI-chemotherapy induction (reduces relapse risk), MRD-positive patients after consolidation, and adult high-risk ALL. Immunotherapy for relapsed/refractory B-ALL: blinatumomab (BiTE antibody linking CD3 T-cells to CD19 B-ALL blasts — 39% CR rate in relapsed ALL, TOWER trial); inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate); tisagenlecleucel (CAR-T cell therapy targeting CD19 — 81% complete remission rate in pediatric/young adult relapsed ALL, ELIANA trial).

Prognosis in ALL varies dramatically by age, molecular subtype, and treatment response. Childhood ALL has been transformed into one of oncology's greatest successes — 5-year overall survival exceeds 90% with modern multi-agent regimens, with long-term cure rates approaching 85-90%. Standard-risk pediatric ALL achieves cure rates of approximately 90-95%. Adult ALL carries a substantially worse prognosis — 5-year overall survival is 35-55% due to higher rates of adverse cytogenetics, particularly the Philadelphia chromosome (BCR-ABL1) present in approximately 25% of adults, older age, and reduced treatment tolerance. Philadelphia chromosome-positive ALL in adults treated with TKI plus chemotherapy achieves complete remission in over 90%, and allogeneic SCT in first remission improves long-term survival to approximately 50-60%. The strongest prognostic factor across all ages is minimal residual disease (MRD) negativity after induction — MRD-negative patients have significantly better outcomes and may avoid transplantation. T-ALL and ETV6-RUNX1-positive ALL carry distinct prognostic profiles. By stage or risk group: standard-risk pediatric B-ALL achieves 5-year survival above 95%; high-risk and very high-risk pediatric ALL approximately 70-85%; adult Ph-negative ALL approximately 40-60%; adult Ph-positive ALL approximately 50% with TKI-based therapy. Relapsed ALL carries poor prognosis — second complete remission rates are approximately 30-50% in adults. Long-term survivors face risks of late effects from treatment including cardiac toxicity from anthracyclines, neurocognitive impairment from CNS-directed therapy, and secondary malignancies, requiring lifelong surveillance.

Most cases of ALL have no identifiable preventable cause, particularly in children. Avoiding unnecessary ionizing radiation exposure (including during pregnancy) and limiting exposure to benzene and other environmental carcinogens may reduce risk. Individuals with Down syndrome and other genetic predisposition syndromes should be monitored with regular blood counts to enable early detection, as they face significantly elevated ALL risk. Prompt evaluation of persistent fatigue, bone pain, bruising, or recurrent infections in children and young adults enables early diagnosis and initiation of highly effective treatment. Chemoprevention strategies are not yet established for ALL, but ongoing genetic research may eventually identify high-risk individuals amenable to targeted monitoring.

Children or adults with unexplained persistent fatigue, pallor, easy bruising, or petechiae (small pinpoint bleeding spots on the skin) require urgent blood count evaluation — these symptoms are characteristic of bone marrow failure as seen in ALL. Recurrent infections that do not resolve with standard antibiotic treatment, bone or joint pain in a child without trauma, and unexplained lymph node enlargement should also prompt prompt medical evaluation. Any new neurological symptoms — including persistent headache, double vision, facial weakness, or altered mental status — require immediate assessment for CNS involvement. Parents who notice that a child is unusually tired, pale, or has lost appetite and weight over several weeks should seek medical evaluation without delay, as early ALL diagnosis dramatically improves cure rates.